[en] OBJECTIVE: Infliximab is an effective treatment for refractory or fistulizing Crohn's disease (CD). However, about 30% of patients do not respond to infliximab for unknown reasons. Identifying predictive factors of response is important for optimizing clinical management and for better understanding infliximab's mechanisms of action. The aim of this study was to assess whether demographic or clinical parameters influence short-term response to infliximab. METHODS: The first 240 CD patients of the Belgian Infliximab Expanded Access Program were studied for response to infliximab treatment and assessed at 4 (refractory luminal CD) or 10 wk (fistulizing CD) after the first infusion. Detailed demographic and clinical information on age, sex, type of disease (fistulizing or refractory), Crohn's Disease Activity Index score, C-reactive protein (CRP), smoking habits, disease duration, localization of disease, concomitant medication, and previous surgery were obtained from all patients. Logistic regression and decision tree analysis were performed. RESULTS: There were 73.5% responders and 26.5% nonresponders to treatment. Stepwise logistic regression identified age (OR = 0.971, 95% CI = 0.947-0.995, p = 0.018), isolated ileitis (OR = 0.359, 95% CI 0.177-0.728, p = 0.004), and previous surgery (OR 0.429, 95% CI = 0.233-0.787, p = 0.006) as inversely correlated with response, whereas isolated colitis (OR = 1.905, 95% CI = 1.010-3.597, p = 0.046) and concomitant immunosuppressive treatment (OR = 2.670, 95% CI = 1.430-5.016, p = 0.0022) were positively correlated with response to infliximab. Surprisingly, smoking habits were not retained as predictors for response. Decision tree analysis provided a working algorithm based on age and immunosuppressive treatment that warrants further exploration. CONCLUSIONS: In this large cohort of infliximab-treated CD patients, young age, Crohn's colitis, and concomitant immunosuppressive treatment were identified as independent variables favoring short-term response to infliximab.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Vermeire, S.
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Carbonez, A.
Van Assche, G.
Noman, M.
Belaiche, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
De Vos, M.
Van Gossum, A.
Pescatore, Pierre ; Université de Liège - ULiège > Relations académiques et scientifiques (Droit)
Elliott M.J., Maini R.N., Feldmann M. (1994) Randomised doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110.
Van Dullemen H.M., Van Deventer S.J.H., Hommes D.W. (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129-135.
Targan S.R., Hanauer S.B., Van Deventer S.J.H. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 337:1029-1035.
Present D.H., Rutgeerts P., Targan S. (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398-1405.
Rutgeerts P., D'Haens G., Targan S. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117:761-769.
Cohen R.D., Tsang J.F., Hanauer S.B. (2000) Infliximab in Crohn's disease: First anniversary clinical experience. Am J Gastroenterol 95:3469-3477.
Farrell R.J., Shah S.A., Lodhavia P.J. (2000) Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 95:3490-3497.
Ricart E., Panaccione R., Loftus E. (2001) Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients. Am J Gastroenterol 96:722-729.
D'Haens G., Van Deventer S., Van Hogezand R. (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease. A European multicenter trial. Gastroenterology 116:1029-1034.
Baert F.J., D'Haens G.R., Peeters M. (1999) Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116:22-28.
D'Haens G., Noman M., Sweijsen C. (2001) An intensified infliximab regimen is effective in Crohn's disease patients refractory to standard infliximab therapy. Acta Gastro-Enterol Belg 64:D44.
Best W.R., Becktel J.M., Singleton J.W. (1976) Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology 70:439-444.
Cosnes J., Carbonnel F., Beaugerie L. (1996) Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 110:424-431.
Munkholm P., Langholz E., Davidsen M. (1994) Frequency of glucocorticoid resistance and dependancy in Crohn's disease. Gut 35:360-362.
Bouhnik Y., Lemann M., Mary J.Y. (1996) Long-term follow up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347:215-219.
Feagan B.G., Rochon J., Fedorak R.N. (1995) Methotrexate for the treatment of Crohn's disease. N Engl J Med , The North American Crohn's Study Group Investigators (comment); 332:330-331.
Maini R.N., Breeveld F.C., Kalden J.R. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1552-1563.
Butcher S., Chahel H., Lord J.M. (2000) Ageing and the neutrophil: No appetite for killing?. Immunology 100:411-416.